---
canonical_name: Tetraselmis chuii
alternate_names: Tetraselmis chui, T. chuii, T. chui, Platymonas chui, Platymonas chuii, TetraSOD, Oceanix
canonical_topic: Tetraselmis chuii for Health & Longevity
short_topic_lc: tetraselmis_chuii
creation_date: 2026-1015-1049
creator_ai_fullname: Gemini 4 Argon
---

# Tetraselmis chuii for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 10/15/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Gemini 4 Argon  

**Also known as:** Tetraselmis chui, T. chuii, T. chui, Platymonas chui, Platymonas chuii, TetraSOD, Oceanix  

  
## Motivation

<!-- Author statement (30.2): This Motivation section was written last, only after all other sections of the document were completed, to ensure it accurately reflects the full scope of the topic. -->

*Tetraselmis chuii* is a microscopic, single-celled green marine alga that has transitioned from a staple feed in ocean aquaculture to a specialized dietary supplement marketed for cellular resilience and exercise recovery. Cultivated in closed, light-controlled marine tanks and freeze-dried into concentrated powders, it attracts health-conscious adults and athletes seeking to support internal cellular defenses against physical and metabolic stress without relying on high-dose synthetic vitamins.  

Originally authorized in Europe as a culinary novel food and later as a dietary supplement, *Tetraselmis chuii* has become the subject of human clinical trials investigating post-exercise recovery and male reproductive health. Because commercial claims frequently extrapolate findings from cell cultures and rodent experiments to human longevity, and because published clinical studies involve small cohorts sponsored by ingredient producers, a rigorous evaluation is needed to separate clinical outcomes from early mechanistic hypotheses.  

This evidence review examines the biological mechanisms, human clinical trial results, metabolic and blood-related side effects, dosing regimens, and sourcing standards for *Tetraselmis chuii*. It evaluates both the case for low-dose cellular signaling and the limitations posed by digestive breakdown and industry-funded evidence.  

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**  

  
## Recommended Reading

Curated academic overviews and foundational primary studies examining the biology, safety, and human physiological effects of *Tetraselmis chuii*.  

<!-- Search provenance (Section 9):
1. Web search (`search_web`): `"Tetraselmis chuii" OR "Tetraselmis chui" OR "TetraSOD" OR "Oceanix" site:foundmyfitness.com OR site:peterattiamd.com OR site:hubermanlab.com OR site:chriskresser.com OR site:lifeextension.com OR site:lifespan.io` -> 0 results across all 6 priority expert platforms.
2. On-site searches via URL retrieval hierarchy (5.2):
   - Rhonda Patrick (`https://www.foundmyfitness.com/search?q=Tetraselmis+chuii` via `ep_d-fetch`): returned "No results found :(".
   - Peter Attia (`https://peterattiamd.com/?s=Tetraselmis+chuii` via `ep_d-fetch`): returned "Nothing Found".
   - Andrew Huberman (`https://www.hubermanlab.com/search?q=Tetraselmis+chuii` via `ep_d-fetch`): returned 0 matching episodes or articles.
   - Chris Kresser (`https://chriskresser.com/?s=Tetraselmis+chuii` via `ep_d-fetch`): returned 0 matching articles on *Tetraselmis chuii*.
   - Life Extension Magazine (`https://www.lifeextension.com/search#q=Tetraselmis%20chuii` via `ep_d-browser`, `ep_d-fetch`, `ep_d-proxy-1`): `ep_d-fetch` returned generic search page with 0 matches; `ep_d-browser` and `ep_d-proxy-1` returned "Access Denied".
   - Lifespan.io (`https://www.lifespan.io/?s=Tetraselmis+chuii` via `ep_d-fetch`): returned "No Articles Found. No Pages Found. No Topics Found."
3. Qualifying academic articles selected from PubMed (`ep_d-pubmed` verified), one per lead author and publication (9.4, 9.14). -->

* [The Potential of Superoxide Dismutase-Rich Tetraselmis chuii as a Promoter of Cellular Health](https://pubmed.ncbi.nlm.nih.gov/40004157/) - Cocksedge et al., 2025  

Synthesizes preclinical and human evidence on *Tetraselmis chuii* rich in superoxide dismutase (SOD, an enzyme converting superoxide radicals into hydrogen peroxide and oxygen), detailing its activation of intracellular antioxidant and anti-inflammatory pathways.  

* [Marine Phytoplankton Improves Exercise Recovery in Humans and Activates Repair Mechanisms in Rats](https://pubmed.ncbi.nlm.nih.gov/33352600/) - Sharp et al., 2021  

Combines a 6-week human resistance-training overreaching trial with a mechanistic rat study, providing both performance recovery data and comprehensive human blood safety panels.  

* [Effects of Tetraselmis chuii Microalgae Supplementation on Ergospirometric, Haematological and Biochemical Parameters in Amateur Soccer Players](https://pubmed.ncbi.nlm.nih.gov/32967151/) - Toro et al., 2020  

Evaluates 30 days of 200 mg/day *Tetraselmis chuii* in athletes, documenting maximal oxygen consumption and hemoglobin increases alongside subclinical shifts in glucose, uric acid, and creatinine.  

* [Superoxide Dismutase-Rich Tetraselmis chuii Supplementation Improves Semen Quality in Idiopathic Infertile Males: A Double-Blind Randomized Placebo-Controlled Trial.](https://pubmed.ncbi.nlm.nih.gov/42093254/) - Leiva et al., 2026  

Examines 90 days of 250 mg/day supplementation in 80 men with unexplained infertility, reporting changes in gonadotropins (pituitary reproductive hormones), sperm motility, deoxyribonucleic acid fragmentation, and live birth outcomes.  

* [Safety assessment of a lyophilized biomass of Tetraselmis chuii (TetraSOD®) in a 90 day feeding study.](https://pubmed.ncbi.nlm.nih.gov/31505236/) - Mantecón et al., 2019  

Establishes the foundational mammalian toxicology profile for freeze-dried *Tetraselmis chuii* strain CCFM03 across doses up to 2,500 mg/kg/day without clinical or histopathological toxicity.  

No articles, podcast episodes, or commentary on *Tetraselmis chuii* were found on the prioritized expert platforms (Rhonda Patrick at FoundMyFitness, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, or Lifespan.io), as this specialized marine microalga has thus far been covered primarily in sports nutrition and phycology journals.  

  
## Grokipedia

<!-- Search provenance (Section 10):
- Searched `grokipedia.com` directly via `ep_d-browser` (`browser_navigate` + `browser_snapshot` on `https://grokipedia.com/search?q=Tetraselmis%20chuii`), returning 4 results with the primary dedicated species entry at `/page/tetraselmis_chui`.
- Verified `https://grokipedia.com/page/tetraselmis_chui` ("Tetraselmis chui — Grokipedia") via both `ep_d-browser` and `ep_d-fetch`. -->

* [Tetraselmis chui](https://grokipedia.com/page/tetraselmis_chui)  

Dedicated species overview of *Tetraselmis chui* (*T. chuii*), covering its marine taxonomy, chlorophyll and carotenoid pigments, polyunsaturated fatty acids, SOD and catalase (CAT, an enzyme decomposing hydrogen peroxide) defenses, and novel food status.  

  
## Examine

<!-- Search provenance (Section 11):
- Searched `examine.com` via `search_web` (`"Tetraselmis chuii" OR "Tetraselmis" OR "TetraSOD" OR "Oceanix" site:examine.com`) and tested the Section 5 retrieval tiers in order on `https://examine.com/supplements/tetraselmis-chuii/`:
  - Tier 1 (`ep_d-browser` `browser_navigate`): blocked by Vercel Security Checkpoint interstitial.
  - Tier 2 (`ep_d-fetch` `fetch`): returned HTTP 429 rate-limit error.
  - Tier 3 (`ep_d-proxy-1` `browser_navigate` + `browser_evaluate`): successfully loaded and verified the primary dedicated intervention page `https://examine.com/supplements/tetraselmis-chuii/` ("Tetraselmis chuii benefits, dosage, and side effects", written by Kamal Patel, updated April 15, 2026) as well as its linked research feed summaries. -->

* [Tetraselmis chuii benefits, dosage, and side effects](https://examine.com/supplements/tetraselmis-chuii/)  

Examine's dedicated intervention page for *Tetraselmis chuii*, summarizing its profile of amino acids, essential fatty acids, and antioxidant micronutrients alongside curated clinical trial summaries on male fertility, body composition, and hormones.  

  
## ConsumerLab

<!-- Search provenance (Section 12):
- Searched `consumerlab.com` via `search_web` (`"Tetraselmis chuii" OR "Tetraselmis" OR "TetraSOD" OR "Oceanix" site:consumerlab.com`) and tested all four Section 5 retrieval tiers in order on `https://www.consumerlab.com/search/?Query=Tetraselmis%20chuii` and `https://www.consumerlab.com/search/?Query=TetraSOD`:
  - Tier 1 (`ep_d-browser` `browser_navigate` + `browser_evaluate`): loaded ConsumerLab search results page ("Check your spelling or browse articles by category"), returning 0 matching articles or product reviews.
  - Tier 2 (`ep_d-fetch` `fetch`): returned HTTP 200 with generic search fallback page and 0 results.
  - Tier 3 (`ep_d-proxy-1` `browser_navigate` + `browser_evaluate`): loaded ConsumerLab search results page with 0 results for both `Tetraselmis chuii` and `TetraSOD`.
  - Tier 4 (`ep_d-proxy-2` `scrape_as_markdown`): returned HTTP 200 markdown of the empty search results page confirming 0 matches. -->

No ConsumerLab articles, product reviews, or quality test reports for *Tetraselmis chuii* were found as of October 15, 2026.  

  
## Systematic Reviews

No systematic reviews or meta-analyses for Tetraselmis chuii were found on PubMed as of October 15, 2026.  

<!-- Search provenance (Section 13):
- Real-time PubMed search via `ep_d-pubmed` (`pubmed_search_articles`) for `("Tetraselmis chuii" OR "Tetraselmis chui" OR "TetraSOD" OR "Tetraselmis") AND (systematic[sb] OR "systematic review" OR "meta-analysis")` returned 1 unrelated environmental engineering meta-analysis on wastewater treatment pond depth (`PMID 38985422`) and 0 systematic reviews or meta-analyses on *Tetraselmis chuii* for human or mammalian health. -->

  
## Mechanism of Action

*Tetraselmis chuii* is a marine green microalga whose freeze-dried biomass (strain CCFM03, marketed as TetraSOD by Fitoplancton Marino, S.L. and Oceanix by Lonza Consumer Health Inc., which fund and co-author most studies—a commercial conflict of interest) contains primary antioxidant enzymes—SOD, CAT, and glutathione peroxidase (GPx, a peroxide-reducing enzyme)—alongside omega-3 polyunsaturated fatty acids (PUFAs, multi-double-bond fats) including eicosapentaenoic acid (EPA), carotenoids, polyphenols, and essential amino acids ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40004157/)).  

A central mechanistic debate concerns bioavailability: whereas early marketing emphasized dietary SOD, bioprocess studies note that unencapsulated algal enzymes undergo proteolytic gut degradation, and human systemic half-life, receptor selectivity, and cytochrome P450 (CYP, liver drug-metabolizing enzymes) pathways remain uncharacterized ([Kwa et al., 2026](https://pubmed.ncbi.nlm.nih.gov/40758577/)). Instead, oral *Tetraselmis chuii* acts indirectly via salivary and gastric release of bioactive peptides and phenolics ([Paterson et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38788650/)). In human muscle, supplementation activates nuclear factor erythroid 2-related factor 2 (NRF2, an antioxidant transcription factor) and sirtuin 1 (SIRT1, a mitochondrial deacetylase), upregulating messenger ribonucleic acid (mRNA, the template for protein synthesis) for glutathione peroxidase 7 (*GPX7*), glutathione-disulfide reductase (*GSR*), glutathione S-transferase Mu 3 (*GSTM3*), and peroxiredoxin 6 (*PRDX6*) (peroxide-neutralizing and glutathione-recycling enzymes), plus mitogen-activated protein kinases (*ERK3*, *p38α*, stress-signaling enzymes) ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40298824/)). In rodent muscle, it suppresses nuclear factor kappa B (NF-κB, an inflammatory transcription factor), myostatin (a muscle-growth inhibitor), and ubiquitin-proteasome ligases (protein-degrading enzymes) while promoting satellite cell myogenesis ([Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)).  

  
## Historical Context & Evolution

Originally described by marine phycologist R. W. Butcher in 1959 (and formerly classified under *Platymonas chui*), *Tetraselmis chuii* was cultivated for decades across global marine hatcheries as a primary live feed for bivalve mollusks, crustacean larvae, and juvenile fish owing to its balanced amino acid and lipid profile and absence of marine phycotoxins ([Mantecón et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31505236/)). Interest in human health optimization emerged after the Spanish marine biotechnology company Fitoplancton Marino, S.L. developed closed-photobioreactor cultivation methods for strain CCFM03 that concentrated intracellular SOD activity above 30,000 IU/g dry weight ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40004157/)).  

Human regulatory adoption began in the European Union (EU), where freeze-dried *Tetraselmis chuii* received Novel Food authorization for culinary foods in 2014 and extended approval for dietary supplements up to 250 mg/day in 2017 ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40004157/)). A 90-day rat feeding study in 2019 reported a no-observed-adverse-effect level (NOAEL, the highest tested dose without toxicity) above 2,500 mg/kg/day ([Mantecón et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31505236/)), and the European Food Safety Authority (EFSA) granted Qualified Presumption of Safety (QPS, a generic safety pre-assessment for biological agents) status for production purposes in 2020 ([EFSA BIOHAZ Panel, 2020](https://pubmed.ncbi.nlm.nih.gov/32874211/)). From 2020 to 2026, human trials reported improvements in post-exercise force recovery, peak oxygen uptake, and infertile semen parameters, while simultaneously revealing null effects on time to exhaustion and inconsistent hematological and body composition responses ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40298824/); [Leiva et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42093254/)).  

  
## Expected Benefits

<!-- Author search statement (16.4): A dedicated search for the complete benefit profile of Tetraselmis chuii—including studies of any design finding no effect or the opposite effect—was conducted across PubMed (`ep_d-pubmed`), EuropePMC, ClinicalTrials.gov (`ep_d-clinicaltrialsgov`), and Examine.com prior to writing this section. All seven published human clinical trial reports (Sharp et al., 2020; Toro et al., 2020; Sharp et al., 2021a; Sharp et al., 2021b; García et al., 2022; Cocksedge et al., 2025; Leiva et al., 2026) and relevant mammalian and in vitro studies were retrieved and cross-checked for both positive and null outcomes. -->

### High 🟩 🟩 🟩

No benefit reaches High: all human clinical trials of *Tetraselmis chuii* come from industry-affiliated research groups without independent replication across separate investigator teams.  

### Medium 🟩 🟩

#### Post-Exercise Neuromuscular Recovery and Strength Preservation

Across three randomized controlled trials (RCTs, studies randomly assigning participants to treatment or control) in 18–22 adults funded and co-authored by distributor Lonza Consumer Health (a conflict of interest), 25 mg/day *Tetraselmis chuii* (Oceanix) accelerated recovery after eccentric exercise or overreaching ([Sharp et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32635494/); rat dose corrected in [Sharp et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35277083/)). Treatment preserved squat-jump power, isometric strength, rate of force development (RFD, explosive force speed), and Perceived Recovery Status (PRS, 0–10 recovery scale), though peak force was unchanged ([Sharp et al., 2021a](https://pubmed.ncbi.nlm.nih.gov/33887828/); [Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)).  

**Magnitude:** +5.93 W/kg higher 24-hour squat-jump power (95% confidence interval [CI, range likely containing the true effect]: 0.31 to 14.32 W/kg), +9.01 kg better 48-hour isometric strength preservation (95% CI: 0.4 to 17.6 kg), 1,253 N/s smaller 48-hour RFD decline (-949 ± 716 vs. -2,202 ± 981 N/s in placebo), and +1.6 points higher 6-week PRS change (+1.1 ± 0.4 vs. -0.5 ± 0.9 in placebo).  

#### Semen Quality and Live Birth Rate in Idiopathic Male Infertility ⭕️ Not Central to Health & Longevity

In a 90-day double-blind RCT of 80 enrolled (62 completed) men with idiopathic (unexplained) infertility ([NCT04864314](https://clinicaltrials.gov/study/NCT04864314)) funded and co-authored by manufacturer Fitoplancton Marino, S.L. (a commercial conflict of interest), 250 mg/day *Tetraselmis chuii* (TetraSOD) improved reproductive fertility parameters rather than general longevity ([Leiva et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42093254/)). Supplementation increased serum gonadotropins, progressive sperm motility, and 9-month follow-up live birth rates while reducing deoxyribonucleic acid (DNA, cellular genetic material) fragmentation, particularly in men with high baseline seminal oxidative stress, though several semen endpoints lacked direct between-group statistical tests.  

**Magnitude:** +45 percentage points higher live birth rate than placebo (66% vs. 21%) at 9-month follow-up, with 90-day progressive sperm motility of 25.11 ± 17.03% in the *Tetraselmis chuii* group vs. 19.62 ± 14.59% in placebo and double-strand sperm DNA fragmentation of 26.60 ± 11.28% vs. 31.41 ± 15.31% in placebo (within-group improvements; not compared between groups).  

### Low 🟩

#### Aerobic Capacity and Endurance Exercise Performance ⚠️ Conflicted

Manufacturer-supplied *Tetraselmis chuii* raised maximal oxygen uptake (VO2max, peak aerobic capacity) in 32 players ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)) and peak oxygen uptake (VO2peak) in 13 men ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40298824/)). Conversely, time to exhaustion and run times ([Sharp et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32635494/)) were unchanged. Overall, endurance performance did not improve.  

**Magnitude:** +3.19 mL/kg/min higher VO2max than placebo (56.74 ± 3.43 vs. 53.55 ± 3.40 mL/kg/min) after 30 days at 200 mg/day and +0.14 L/min within-group VO2peak increase at 25 mg/day (vs. -0.03 L/min in placebo; post-treatment between-group difference non-significant), with no significant difference in time to exhaustion or running speed.  

#### Erythropoiesis, Hematological Indices, and Anabolic Hormones ⚠️ Conflicted

In 32 men, 200 mg/day raised hemoglobin ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)). Conversely, two RCTs found no hemoglobin gain despite within-group erythropoietin (EPO, red-cell hormone), insulin-like growth factor 1 (IGF-1, growth hormone), and lymphocyte rises ([García et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35627597/); [Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)). Overall, hemoglobin did not reliably improve.  

**Magnitude:** +1.34 g/dL higher post-treatment hemoglobin than placebo (16.58 ± 0.74 vs. 15.24 ± 0.84 g/dL) in one 30-day trial, and within-group lymphocyte change from 1.58 ± 0.35 to 1.92 ± 0.45 × 10³/µL at 25 mg/day vs. 1.66 ± 0.55 to 1.50 ± 0.53 × 10³/µL in placebo (not compared between groups), alongside null hemoglobin differences in two subsequent RCTs.  

#### Body Composition (Muscle Mass and Fat Mass Percentage) ⚠️ Conflicted

In 46 men, 25 and 200 mg/day *Tetraselmis chuii* yielded within-group skinfold muscle gains and fat reductions without between-group significance ([García et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35627597/)). Conversely, 200 mg/day in 32 players did not alter fat or muscle mass ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)). Overall, body composition did not improve between groups.  

**Magnitude:** Within-group muscle mass change from 47.39 ± 2.50% to 48.91 ± 2.10% (25 mg/day) and 47.12 ± 2.56% to 48.28 ± 2.10% (200 mg/day) vs. 47.82 ± 2.75% to 47.89 ± 2.81% in placebo, and fat mass change from 12.98 ± 2.34% to 11.08 ± 2.93% vs. 12.84 ± 2.11% to 13.94 ± 2.02% in placebo (not compared between groups at follow-up; null in a second 30-day RCT).  

### Speculative 🟨

#### Skeletal Muscle Antioxidant and Stress-Response Gene Expression

In a 14-day human crossover RCT (13 men), 25 mg/day *Tetraselmis chuii* increased resting muscle mRNA of *NRF2* (1.62-fold), *SIRT1* (1.73-fold), *GPX7*, *GSR*, *GSTM3*, and *PRDX6* ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40298824/)). Functional protein levels were unmeasured.  

#### Post-Exercise Muscle Damage and Mucosal Immune Biomarkers

In 18–19 adults taking 25 mg/day, *Tetraselmis chuii* lowered 24-hour log serum creatine kinase (CK, muscle damage enzyme) ([Sharp et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32635494/)). It also preserved salivary immunoglobulin A (sIgA, mucosal antibody) ([Sharp et al., 2021a](https://pubmed.ncbi.nlm.nih.gov/33887828/)).  

#### Systemic and Hepatic Metabolic Syndrome Attenuation

In cafeteria-diet rats, 8 weeks of *Tetraselmis chuii* raised hepatic glutathione and GPx activity. It also lowered plasma oxidized low-density lipoprotein (oxLDL, pro-atherogenic lipid) and raised interleukin-10 (IL-10, anti-inflammatory cytokine) ([Gil-Cardoso et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36235679/)).  

#### Skeletal Muscle Satellite Cell Myogenesis and Proteolysis Suppression

In exercised rats given 2.55–5.1 mg/kg/day ([Sharp et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35277083/)), *Tetraselmis chuii* elevated MyoD (muscle-differentiation protein) and NCAM (muscle-repair protein). It also suppressed myostatin, MuRF-1, and MAFbx (muscle-breakdown enzymes) ([Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)).  

#### Telomere Length Preservation Under Oxidative Stress

In human fibroblasts exposed to hydrogen peroxide for 8 weeks, *Tetraselmis chuii* extracts slowed telomere shortening. Treatment also reduced critically short telomeres (<3 kilobase pairs) and increased median telomere length ([Blázquez-Moreno et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41910429/)).  

#### Colonic Microbiota Modulation and Short-Chain Fatty Acid Production

In 72-hour human fecal fermentations, digested *Tetraselmis chuii* suppressed *Clostridium* and *Enterobacteriaceae* while enriching *Akkermansia* and *Butyricimonas*. It also stimulated acetate (20 mM), propionate (>5 mM), and butyrate (>2 mM) production ([Majchrzak et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40565715/)).  

  
## Benefit-Modifying Factors

* **Genetic polymorphisms:** Although no pharmacogenetic trials have tested *Tetraselmis chuii* directly, functional polymorphisms in *NFE2L2* (encoding NRF2) or *SOD2* (encoding mitochondrial manganese SOD) may theoretically alter individual transcriptional responsiveness to microalgal redox signaling ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40298824/)).  
* **Baseline biomarker levels:** Lower baseline antioxidant expression strongly predicts larger benefit, evidenced by negative correlations ($r = -0.6$ to $-0.9$) across 53 muscle transcripts ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40298824/)) and greater sperm DNA protection in men with elevated seminal oxidation-reduction potential ([Leiva et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42093254/)).  
* **Sex-based differences:** Five of seven human trials enrolled men exclusively ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/); [Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40298824/)), and the two mixed-sex recovery trials ([Sharp et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32635494/); [Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)) did not disaggregate outcomes by sex, leaving female-specific efficacy unestablished.  
* **Pre-existing health conditions and training load:** Benefits manifest primarily under high oxidative stress—such as intentional resistance overreaching ([Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)) or oxidative idiopathic infertility ([Leiva et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42093254/))—whereas non-fatigued strength and rested endurance capacity show minimal response ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40298824/)).  
* **Age-related considerations:** All human trials have studied young adults (mean ages 20–37 years); older adults experiencing age-related declines in skeletal muscle *NRF2* and *SIRT1* activity could theoretically benefit more, but clinical efficacy in older populations remains untested ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40004157/)).  

  
## Potential Risks & Side Effects

<!-- Author search statement (18.4): A dedicated search for the complete side effect and toxicology profile of Tetraselmis chuii (and commercial formulations TetraSOD and Oceanix)—including studies of any design finding no excess risk or lower risk—was performed across drug and medical reference sources (drugs.com, Mayo Clinic, MedlinePlus, RxList), European Food Safety Authority (EFSA) and Spanish AESAN regulatory opinions, ClinicalTrials.gov adverse event tables (NCT04864314), and PubMed (`ep_d-pubmed`) prior to writing this section. -->

### High 🟥 🟥 🟥

No risk reaches High: human randomized trials across multiple research groups have reported zero clinical adverse events, and no multi-group trial has replicated a clinically significant laboratory abnormality.  

### Medium 🟥 🟥

No risk reaches Medium: the subclinical glucose, uric acid, creatinine, and platelet shifts observed in single Spanish male trials were absent in an independent 6-week human safety trial.  

### Low 🟥

#### Elevations in Fasting Glucose, Uric Acid, and Serum Creatinine ⚠️ Conflicted

In 32 men, 200 mg/day *Tetraselmis chuii* raised fasting glucose, uric acid, and creatinine versus placebo within normal limits ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)). Conversely, 25 mg/day in 22 adults did not alter glucose or creatinine ([Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)). Overall, shifts appear restricted to 200 mg/day.  

**Magnitude:** +5.91 mg/dL higher post-treatment fasting glucose than placebo (91.01 ± 5.40 vs. 85.10 ± 6.30 mg/dL), +0.29 mg/dL higher uric acid than placebo (6.04 ± 0.77 vs. 5.75 ± 0.73 mg/dL), and +0.10 mg/dL higher serum creatinine than placebo (1.07 ± 0.12 vs. 0.97 ± 0.10 mg/dL) at 200 mg/day, vs. no significant difference at 25 mg/day.  

#### Reductions in Platelet Count and Mean Platelet Volume ⚠️ Conflicted

Two male RCTs reported lower mean platelet volume (MPV, average platelet size) at 200 mg/day ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)) and lower platelet counts at 25 mg/day ([García et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35627597/)). Conversely, a third RCT found no platelet changes ([Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)). Overall, shifts remained subclinical without bleeding.  

**Magnitude:** -0.97 fL lower post-treatment MPV than placebo (8.04 ± 1.05 vs. 9.01 ± 1.20 fL) at 200 mg/day and within-group platelet count change from 268.58 ± 40.12 to 222.33 ± 21.03 × 10³/µL at 25 mg/day vs. 211.81 ± 48.01 to 196.00 ± 20.16 × 10³/µL in placebo (not compared between groups; null in a third 6-week RCT).  

### Speculative 🟨

#### Hepatic Pro-Inflammatory Cytokine Transcript Upregulation

In human hepatoma (HepG2, liver cancer) cells, *Tetraselmis chuii* was non-cytotoxic. However, exposure upregulated mRNA of tumor necrosis factor-alpha (*TNF-α*), interleukin-1 beta (*IL-1β*), and interleukin-6 (*IL-6*) (pro-inflammatory signaling proteins) ([Taroncher et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36437517/)).  

#### Bioaccumulation of Heavy Metals and Polycyclic Aromatic Hydrocarbons

Marine *Tetraselmis* species biosorb trace metals and polycyclic aromatic hydrocarbons (PAHs, toxic combustion pollutants) from seawater ([Cheng et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41152593/)). Uncertified open-pond biomass may transfer contaminants if water purity is unmonitored ([Taroncher et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36437517/)).  

#### Purine-Mediated Hyperuricemia in Susceptible Individuals

Rapidly dividing microalgae contain concentrated nucleic acids and purines that metabolize into uric acid ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)). High doses (200–250 mg/day) could theoretically trigger gout flares in hyperuricemia (excess blood uric acid).  

  
## Risk-Modifying Factors

* **Genetic polymorphisms:** Variants in *SLC2A9* and *ABCG2* (genes encoding kidney and gut uric acid transporters) impair urate excretion and may theoretically increase susceptibility to the purine-associated uric acid elevation observed at 200 mg/day ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)).  
* **Baseline biomarker levels:** High-normal baseline fasting glucose, serum uric acid, or creatinine, or low-normal platelet counts, narrow the safety margin for the subclinical shifts reported during 30- to 60-day supplementation ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/); [García et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35627597/)).  
* **Sex-based differences:** All statistically significant increases in glucose, uric acid, and creatinine and reductions in platelet indices were reported in all-male cohorts ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)), whereas mixed-sex trials did not publish sex-stratified safety panels ([Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)).  
* **Pre-existing health conditions:** Gout, uric acid nephrolithiasis (kidney stones), chronic kidney disease, thrombocytopenia (low platelet count), or autoimmune thyroid disease increase vulnerability to microalgal purines, platelet shifts, or trace marine iodine ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/); [Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40004157/)).  
* **Age-related considerations:** Older adults with age-related declines in estimated glomerular filtration rate (eGFR, kidney filtration rate) or insulin sensitivity may experience larger glycemic, creatinine, or urate shifts at 200–250 mg/day than young athletes ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)).  

  
## Key Interactions & Contraindications

<!-- Author search statement (20.1): A dedicated search for published human drug interaction and pharmacokinetic studies of Tetraselmis chuii (and commercial formulations TetraSOD and Oceanix) was performed on PubMed (`("Tetraselmis chuii" OR "TetraSOD" OR "Oceanix") AND ("interaction" OR "pharmacokinetics" OR "cytochrome" OR "warfarin" OR "adverse")`) and drug reference databases (drugs.com, MedlinePlus) prior to writing this section. Zero human pharmacokinetic or drug-interaction studies have been published; interactions below are therefore marked (theoretical). -->

* **Prescription anticoagulants and antiplatelets (warfarin, apixaban, rivaroxaban, clopidogrel):** Caution (theoretical) — mild reductions in human platelet count and MPV ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/); [García et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35627597/)) could theoretically increase bruising or bleeding risk; monitoring platelet counts and coagulation parameters is standard.  
* **Over-the-counter antiplatelet and nonsteroidal anti-inflammatory drugs (aspirin, ibuprofen, naproxen):** Monitor (theoretical) — concurrent use could theoretically add to minor platelet volume and count reductions observed in 30- to 60-day human trials ([García et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35627597/)); limiting high-dose co-administration if bruising occurs is standard.  
* **Urate-lowering prescription medications (allopurinol, febuxostat, probenecid):** Monitor (theoretical) — 200 mg/day *Tetraselmis chuii* slightly increased serum uric acid (+0.28 mg/dL from baseline) in healthy men ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)), which could partially offset urate lowering; the 25 mg/day dose avoids this shift.  
* **Antidiabetic medications (metformin, glimepiride, semaglutide, insulin):** Monitor (theoretical) — 200 mg/day increased fasting glucose by 8.0 mg/dL in athletes ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)); monitoring fasting glycemia or using 25 mg/day, where glucose was unchanged ([Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)), mitigates this effect.  
* **Iodine-containing and antiplatelet supplements (kelp, potassium iodide, high-dose omega-3 fish oil, *Ginkgo biloba*):** Monitor (theoretical) — marine microalgae contribute trace seawater iodine and EPA ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40004157/)), creating additive iodine exposure with kelp or additive antiplatelet effects with fish oil and *Ginkgo biloba*.  
* **High-volume resistance and eccentric exercise protocols:** Potentiating interaction — pairing 25 mg/day *Tetraselmis chuii* with intense resistance overreaching or cross-training selectively preserves explosive RFD and lowers post-exercise CK compared with training alone ([Sharp et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32635494/); [Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)).  

**Populations who should avoid Tetraselmis chuii:**  

* **Children and adolescents under 18 years of age:** European Union Novel Food authorization for *Tetraselmis chuii* food supplements and all published human clinical trials restrict use to adults aged ≥18 years ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40004157/); [EFSA BIOHAZ Panel, 2020](https://pubmed.ncbi.nlm.nih.gov/32874211/)).  
* **Pregnant and lactating women:** Excluded from all human clinical trials and European Union food supplement safety evaluations due to the absence of human gestational safety data ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40004157/)).  
* **Individuals with thrombocytopenia or active bleeding disorders:** Excluded based on hematological inclusion criteria and statistically significant within-group reductions in platelet count and MPV in two human trials ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/); [García et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35627597/)).  
* **Individuals with uncontrolled gout or hyperuricemia:** High-dose supplementation (200 mg/day) significantly increased serum uric acid in human testing ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)).  

  
## Risk Mitigation Strategies

Parameters below without a citation reflect common practice.  

* **Low-dose selection (25 mg/day):** Using 25 mg/day instead of 200–250 mg/day prevents the fasting glucose, uric acid, and creatinine rises seen at 200 mg/day ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)) while preserving *NRF2* signaling benefits ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40298824/)).  
* **Baseline and 60-day platelet checks:** To mitigate mild drops in platelet count and MPV, protocols run a complete blood count (CBC, blood cell panel) at baseline and 60 days, pausing if platelets fall below reference ranges ([García et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35627597/)).  
* **Closed-photobioreactor sourcing:** To prevent bioaccumulated heavy metal and PAH ingestion from coastal waters ([Cheng et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41152593/)), quality protocols use closed-photobioreactor biomass verified by a batch certificate of analysis (CoA, independent lab purity report) ([Mantecón et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31505236/)).  
* **Metabolic monitoring on 200–250 mg/day:** To mitigate uric acid, glucose, and creatinine rises on high doses, protocols pair ≥2.5 L/day hydration with reducing to 25 mg/day ([Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)) if values exceed normal reference limits ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)).  

  
## Therapeutic Protocol

Parameters below without a citation reflect common practice.  

* **Standard low-dose protocol:** 25 mg/day of freeze-dried *Tetraselmis chuii* strain CCFM03 (TetraSOD or Oceanix, ≥30,000 IU/g SOD), popularized by Lonza and Fitoplancton Marino trials for exercise recovery and muscle *NRF2*/*SIRT1* signaling ([Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/); [Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40298824/)).  
* **Alternative high-dose protocols:** Competing regimens use 200 mg/day for 30 days to target VO2max and hemoglobin in athletes ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)) or 250 mg/day (the EU supplement maximum) for 90 days in male infertility ([Leiva et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42093254/)).  
* **Time of day and dosing frequency:** Taken orally as a single once-daily capsule (never split-dosed) in the morning with breakfast at 8:00–10:30 AM ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40298824/); [García et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35627597/)) or 30 minutes pre-workout ([Sharp et al., 2021a](https://pubmed.ncbi.nlm.nih.gov/33887828/)).  
* **Expected half-life and washout:** Systemic human half-life is unquantified because microalgal biomass undergoes gastric proteolysis ([Kwa et al., 2026](https://pubmed.ncbi.nlm.nih.gov/40758577/)); induced transcriptional and hematological shifts resolve within a 14- to 30-day washout ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40298824/); [García et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35627597/)).  
* **Genetic polymorphisms:** No pharmacogenetic dosing guidelines exist, though in individuals with *SLC2A9* or *ABCG2* hyperuricemia risk variants, the 25 mg/day regimen avoids the purine load of 200–250 mg/day regimens ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)).  
* **Sex-based and age-related considerations:** Mixed-sex trials used 25 mg/day in men and women without adjustment ([Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)); in older adults (unstudied above age 45), 25 mg/day avoids high-dose renal and glycemic shifts ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)).  
* **Baseline biomarkers and health conditions:** Men with high seminal oxidation-reduction potential (>1.36 mV/10⁶ sperm/mL) match 250 mg/day ([Leiva et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42093254/)), while 25 mg/day ([Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)) avoids 200 mg/day glucose and urate rises ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)).  

  
## Discontinuation & Cycling

* **Short-term versus lifelong use:** *Tetraselmis chuii* is studied strictly as a short-term intervention (14–90 days) rather than a lifelong daily supplement, with no human safety data beyond 3 months ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40298824/); [Leiva et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42093254/)).  
* **Absence of withdrawal or rebound effects:** In a 60-day human RCT with a 30-day post-supplementation de-adaptation assessment, erythropoietin, IGF-1, free testosterone, and leukocyte counts returned gradually toward baseline without endocrine rebound suppression or withdrawal symptoms ([García et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35627597/)).  
* **Tapering protocol:** Abrupt cessation is standard across all human crossover and parallel trials ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40298824/); [Leiva et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42093254/)); dose tapering is unnecessary.  
* **Cycling recommendations:** Because human trials span 2–12 weeks, users typically cycle 6–12 weeks of daily use followed by a 2–4 week washout ([García et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35627597/)), or use 14-day loading before peak training blocks ([Sharp et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32635494/)).  

  
## Sourcing and Quality

* **Source, purity, and cultivation method:** Freeze-dried biomass cultivated in closed tubular photobioreactors using sterilized marine water rather than open ponds prevents environmental uptake of heavy metals, PAHs, and marine biotoxins ([Mantecón et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31505236/); [Cheng et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41152593/)).  
* **Labels and testing:** Quality markers include standardization to ≥30,000 IU/g of SOD activity, absence of viable algal cells per EFSA QPS rules ([EFSA BIOHAZ Panel, 2020](https://pubmed.ncbi.nlm.nih.gov/32874211/)), and third-party CoA testing for lead, cadmium, mercury, arsenic, and microbes ([Taroncher et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36437517/)).  
* **Reputable brands:** Patented **TetraSOD** (Fitoplancton Marino, S.L., strain CCFM03) and **Oceanix** (Lonza Consumer Health Inc.) are the only ingredients validated in human RCTs and Organisation for Economic Co-operation and Development (OECD, international toxicology standard) studies ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40004157/); [Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)).  
* **Formulation and storage stability:** Freeze-dried capsules in desiccant-lined blister packs protect heat-labile algal enzymes and chlorophylls from moisture and oxidative browning ([Fanari et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40238484/)), unlike heat-extruded gummies or unsealed bulk powders.  

  
## Practical Considerations

* **Time to effect:** Muscle *NRF2*/*SIRT1* gene upregulation, VO2peak gains, and post-exercise strength preservation emerge after 14 days ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40298824/); [Sharp et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32635494/)), hematological shifts take 30–60 days ([García et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35627597/)), and sperm improvements take 90 days ([Leiva et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42093254/)).  
* **Common pitfalls:** Users frequently assume higher doses (200–250 mg/day) yield greater ergogenic effects, whereas 25 mg/day matched or outperformed 200 mg/day for hormonal and hematological responses ([García et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35627597/)) without provoking high-dose glucose, uric acid, and creatinine rises ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)).  
* **Regulatory status:** Authorized in the European Union as a Novel Food in 2014 and as a food supplement ingredient up to 250 mg/day in 2017 ([Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40004157/)), and granted EFSA QPS status for production purposes in 2020 ([EFSA BIOHAZ Panel, 2020](https://pubmed.ncbi.nlm.nih.gov/32874211/)).  
* **Cost, accessibility, and sensory profile:** Commercially accessible online for $0.50–$1.50/day as a single small capsule; opening capsules or using loose powder is discouraged due to an intense fishy, shellfish flavor and odor ([Fanari et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40238484/)).  

  
## Interaction with Foundational Habits

* **Sleep:** Indirect interaction — *Tetraselmis chuii* is non-stimulatory and does not disrupt sleep when taken in the morning ([García et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35627597/)). During 5-week overreaching, 25 mg/day improved subjective recovery scores, though researchers emphasized that adequate sleep duration remains essential to resolve central nervous system fatigue ([Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)).  
* **Nutrition:** Indirect interaction — simulated human digestion shows *Tetraselmis chuii* supplies highly bioaccessible potassium (91.1–100%) and magnesium (68.0–92.2%) but negligible bioaccessible iron (0.5% vs. 83.4% in *Chlorella vulgaris*) ([Gao et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41625284/)). Protocols pair mealtime capsules with bioavailable dietary iron sources when iron-deficient.  
* **Exercise:** Potentiating interaction — unlike high-dose direct vitamin C and E antioxidants that blunt exercise-induced adaptations, 25 mg/day *Tetraselmis chuii* taken during resistance overreaching or cycling preserved explosive RFD and lowered CK while upregulating muscle *NRF2* and *SIRT1* and increasing VO2peak ([Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/); [Cocksedge et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40298824/)).  
* **Stress management:** None to indirect interaction — in endurance athletes completing a muscle-damaging cross-training bout, 25 mg/day *Tetraselmis chuii* for 14 days had no effect on acute post-exercise salivary cortisol responses compared with placebo ([Sharp et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32635494/)), indicating it does not substitute for psychological or autonomic stress management.  

  
## Monitoring Protocol & Defining Success

Before starting *Tetraselmis chuii* supplementation, baseline laboratory testing includes a comprehensive metabolic panel (CMP, a blood panel measuring fasting glucose, electrolytes, and kidney and liver function), serum uric acid, and a complete blood count (CBC), alongside baseline countermovement jump or isometric pull force metrics when targeting athletic recovery. Follow-up laboratory and functional testing is typically performed at 2 weeks and 6 weeks for standard 25 mg/day regimens, and at 4 weeks, 8 weeks, and 12 weeks (then every 3 to 6 months if cycled) for 200 to 250 mg/day regimens, with discontinuation if no measurable functional or biomarker benefit is evident by 6 to 8 weeks.  

* **Perceived post-exercise recovery:** Tracked weekly on the 0–10 PRS scale during intensive training blocks ([Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)).  
* **Delayed-onset muscle soreness and readiness:** Assessed via subjective muscle soreness and jump readiness 24–48 hours after strenuous sessions ([Sharp et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32635494/)).  

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
| :--- | :--- | :--- | :--- |
| **Fasting Blood Glucose** | 70–99 mg/dL (standard reference range) | Safety check: 200 mg/day raised fasting glucose (+8.0 mg/dL) in a 30-day trial ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)). | Measured after an 8–12 hour overnight fast; protocols reduce to 25 mg/day or stop if ≥100 mg/dL. |
| **Serum Uric Acid** | 3.5–7.2 mg/dL in men; 2.6–6.0 mg/dL in women (standard reference range) | Safety check: 200 mg/day increased serum uric acid in athletes ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)). | Morning fasting blood draw; protocols discontinue use if uric acid rises above the upper reference limit. |
| **Serum Creatinine** | 0.7–1.3 mg/dL in men; 0.6–1.1 mg/dL in women (standard reference range) | Safety check: 200 mg/day elevated creatinine from 0.96 to 1.07 mg/dL ([Toro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32967151/)). | Strenuous exercise is avoided for 24 hours before testing to prevent muscle breakdown confounding. |
| **Platelet Count and Mean Platelet Volume (MPV)** | Platelets: 150–450 × 10³/µL; MPV: 7.5–11.5 fL (standard reference range) | Safety check: two trials noted mild drops in platelet count or MPV ([García et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35627597/)). | Measured on standard ethylenediaminetetraacetic acid (EDTA, blood-tube anticoagulant) whole-blood CBC; protocols stop if platelets drop below 150 × 10³/µL. |
| **Serum Creatine Kinase (CK)** | No established target; track 24–48 hour post-exercise attenuation relative to individual baseline | Expected to change: 25 mg/day lowered 24-hour post-damage log serum CK vs. placebo ([Sharp et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32635494/)). | Sampled 24 hours after a standardized eccentric or cross-training session. |
| **Countermovement Jump or Isometric RFD** | No established target; track maintenance or recovery to ≥95% of individual baseline | Expected to change: 25 mg/day preserved 48-hour and 6-week RFD ([Sharp et al., 2021b](https://pubmed.ncbi.nlm.nih.gov/33352600/)). | Assessed on a force plate at a consistent time of day after a standardized warm-up. |

  
## Emerging Research

* **Lower-Dose Male Infertility Trial ([NCT06324071](https://clinicaltrials.gov/study/NCT06324071)):** This 50-man study evaluates 125 mg/day *Tetraselmis chuii* for 90 days on seminal oxidation-reduction potential and DNA fragmentation; its registered completion date passed in December 2025 with no results posted—positive findings would validate half-dose fertility regimens, whereas null results would challenge reproductive efficacy.  
* **Telomere Attrition Under Oxidative Stress:** [An antiageing telomere-protective effect of superoxide dismutase-rich Tetraselmis chui in human cells.](https://pubmed.ncbi.nlm.nih.gov/41910429/) (Blázquez-Moreno et al., 2026; [10.1177/02601060261431078](https://doi.org/10.1177/02601060261431078)) showed *Tetraselmis chuii* extracts slowed telomere shortening and reduced critically short telomeres (<3 kilobase pairs) in hydrogen peroxide-stressed human fibroblasts over 8 weeks, supporting cellular aging research.  
* **Biogenic Extracellular Vesicles ("Nanoalgosomes"):** [Aerosolized microalgal derived extracellular vesicles reduce oxidative stress and inflammation in bronchial epithelial macrophage cocultures at the air liquid interface.](https://pubmed.ncbi.nlm.nih.gov/42387133/) (Darwish et al., 2026) and [Engineered microalgal extracellular vesicles for efficient doxorubicin delivery and improved therapeutic efficacy in breast cancer.](https://pubmed.ncbi.nlm.nih.gov/41660122/) (Adamo et al., 2026) motivate human bioavailability trials.  
* **Oral Enzyme Loss and Hepatic Cytokines:** [High-productive recovery and purification of superoxide dismutase from Tetraselmis chuii using integrated ultrasonication-aqueous two-phase system.](https://pubmed.ncbi.nlm.nih.gov/40758577/) (Kwa et al., 2026) notes gut SOD loss and [Evaluation of cytotoxicity, analysis of metals and cumulative risk assessment in microalgae.](https://pubmed.ncbi.nlm.nih.gov/36437517/) (Taroncher et al., 2023) notes HepG2 cytokine rises, warranting human trials.  

  
## Conclusion

*Tetraselmis chuii* is a marine green microalga whose freeze-dried biomass is rich in antioxidant enzymes, essential amino acids, and omega-3 fatty acids. Human clinical trials provide moderate-level evidence from a single research group that a low daily dose accelerates the recovery of explosive muscle strength and perceived recovery after intense training, and that a higher daily dose improves sperm motility and live birth rates in men with unexplained infertility. By contrast, evidence for increased aerobic capacity, red blood cell production, hormone shifts, and body composition changes is low in certainty and conflicted across trials, while changes in resting muscle gene expression, gut bacteria, and telomere length remain speculative findings from laboratory or unvalidated biomarker studies.  

Safety assessments indicate that low daily doses are well tolerated without blood chemistry abnormalities. At higher daily doses, one human trial recorded small, symptomless increases in fasting blood sugar, uric acid, and kidney creatinine markers alongside minor reductions in blood platelet size and count, though values remained within normal reference limits and a separate six-week trial found no adverse shifts.  

Across the entire literature, confidence is constrained by small, predominantly young male study cohorts, short trial durations of two to twelve weeks, and a pervasive financial conflict of interest: virtually every human trial has been funded, supplied with product, or co-authored by employees of the commercial producer Fitoplancton Marino, S.L. or its distributor Lonza Consumer Health Inc.  

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**  



